Diversity, Equity and Inclusion:
As members of PhRMA, we believe improving human life means celebrating human diversity
All in for Diversity, Equity & Inclusion at Sanofi
We have around 100,000 (exact figure in 2021 is 95,442) employees with over 142 nationalities between us, but diversity on its own is not enough. That’s why we work constantly to ensure our workplace is also inclusive, where everyone can be their true selves, comfortable to speak up and brave enough to speak out. Building such an environment also directly influences and impacts how we engage with patients and customers, as well as with the communities where we work.
Building Responsible Leadership
By 2025, 50% of our senior leaders and 40% of our executives will be women. The other diversity strands we’re focusing on are age, race, ethnicity, faith, disability, and the LGBTQIA+ community. We’re striving to ensure they are equally represented in our leadership and teams across Sanofi and will set key performance indicators that are locally relevant in each country. Other diversity strands that are not necessarily protected characteristics by law in certain countries, such as socio-economic background, are also considered in our diversity and inclusion strategy.
Supplier Diversity
We have a Global Supplier Diversity program in place to increase the inclusion of historically disadvantaged or under-represented groups in our sourcing processes. We have a partnership with WeConnect International to increase our collaboration and engagement with women-owned businesses, and support women’s economic empowerment. On International Women’s Day March 8, 2022, we made a public commitment to double our woman-owned business spend by 2025 and spend over €1.5 billion with small and diverse businesses by 2025.
Gender Balance
Sanofi has committed to achieving gender balance in management by 2025, by reaching 40% of women top executives and 50% of women senior leaders. As of March 2022, we have 35.1% of our top executives and 40.4% of our senior leaders who are women. To facilitate our efforts, we have implemented gender neutral parental leave globally, regularly monitor our efforts through dashboards and introduced awareness programs for managers.
Environmental Sustainability:
As members of PhRMA, we believe a healthy environment is essential for improving human life
Planet Mobilization
Sanofi has committed to monitoring and reducing its environmental impact through its strategy, “Planet Mobilization,” to limit the impact on the environment at every stage of the product lifecycle: from the raw materials we use in our medicines, devices and services to their potential end-of-life impact on human health and the environment.
Carbon
• Achieve carbon neutrality by 2030 on scope 1, 2 and 3 (Science Based Target initiative approved targets)
• Reduce GHG emissions from Sanofi activities by 55% and from scope 3 by 14% by 2030 (2019 base year)
• Reach 100% renewable electricity across all global operations by 2030 and
• Achieve a carbon neutral car fleet by 2030.
• Reduce GHG emissions from Sanofi activities by 55% and from scope 3 by 14% by 2030 (2019 base year)
• Reach 100% renewable electricity across all global operations by 2030 and
• Achieve a carbon neutral car fleet by 2030.
EcoDesign
Improve the environmental profile of our products with eco-design approach for all new products by 2025 and by ending the use of plastic in blister packs for all our vaccines by 2027. This is a truly complex industrial endeavor that will address the problem of plastic waste in the environment.
Environmental Goals:
1. Reach Carbon Neutrality by 2030 and Net Zero Emissions by 2050
2. Limit our environmental footprint and adopt circular solutions
3. Improve environmental profile of our products
2. Limit our environmental footprint and adopt circular solutions
3. Improve environmental profile of our products
Access & Affordability:
As members of PhRMA, we believe that living our mission of improving human life relies on broad access to medicines
Humanitarian Programs
Even in countries with developed healthcare systems, patients may encounter difficulties accessing treatment for many reasons. Some people may have limited or no health insurance, or their country’s public health system does not reimburse the price of treatments. To help ensure no one falls through the gaps, we also work with health authorities and patient groups to supply free treatment to people with lysosomal disorders. First launched in the US in 1991, the Charitable Access Program now supports more than 3,300 people with five types of lysosomal storage disorders in over 70 countries across six continents. In 2021, a total of 110,000 treatment vials were donated, enabling more than 1,000 patients with rare diseases to receive treatment.
Sponsorship
Alkermes is proud to be part of the broader healthcare community supporting those with addiction, serious mental illness and cancer. In 2020 and 2021, we sponsored non-profit organizations such as the National Alliance on Mental Illness (NAMI), the Partnership to End Addiction and the American Cancer Society while continuing to bring awareness to programs and initiatives of other organizations that work to improve the lives of persons affected by mental illness, substance use disorder and cancer.
Sanofi Global Health
Sanofi aims to use its expertise to reinforce affordable access and quality care to ensure underserved populations receive the treatments they need. Sanofi has created Sanofi Global Health (“SGH”), a non-profit business unit that operates in some of the least developed regions of the world, offering at the onset 30 of Sanofi’s most essential medicines, including treatments for cardiovascular diseases, diabetes, cancer, and tuberculosis.
Our pricing principles in the US
Too many Americans still struggle to pay for their medicines and treatments due to out-of-pocket drug costs. Our Pricing Principles, launched in 2017, aim to promote a culture of transparency that is adopted not only in our industry, but across healthcare. The results can be seen in our 2022 Pricing Principles report that shows the average net price of our US medicines portfolio has declined for the sixth year in a row.